Where Does Wall Street Think Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Stock Will Go?

Thursday, October 14, 2021 02:24 PM | InvestorsObserver Analysts

Mentioned in this article

Wall Street is positive on Bio-Rad Laboratories, Inc. Class A Common Stock (BIO). On average, analysts give BIO a Strong Buy rating. The average price target is $843.333, which means analysts expect the stock to climb by 16.12% over the next twelve months. That average ranking earns BIO an Analyst Rating of 75, which is better than 75% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating BIO a Strong Buy today. Find out what this means to you and get the rest of the rankings on BIO!
See Full BIO Report

Why are Analyst Ratings Important?

Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers. InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.

What's Happening With Bio-Rad Laboratories, Inc. Class A Common Stock Stock Today?

Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) stock is trading at $726.23 as of 2:04 PM on Thursday, Oct 14, a gain of $17.07, or 2.41% from the previous closing price of $709.16. The stock has traded between $718.22 and $729.17 so far today. Volume today is light. So far 37,873 shares have traded compared to average volume of 136,952 shares. Click Here to get the full Stock Report for Bio-Rad Laboratories, Inc. Class A Common Stock stock.

Share this article:

Related Articles